Fisher Asset Management LLC Has $9.36 Million Position in Vericel Co. (NASDAQ:VCEL)

Fisher Asset Management LLC raised its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 16.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 170,500 shares of the biotechnology company's stock after buying an additional 23,937 shares during the quarter. Fisher Asset Management LLC owned about 0.35% of Vericel worth $9,362,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of VCEL. International Assets Investment Management LLC increased its holdings in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after buying an additional 619 shares during the period. Arcadia Investment Management Corp MI bought a new stake in shares of Vericel during the 4th quarter valued at approximately $48,000. Farther Finance Advisors LLC grew its holdings in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in shares of Vericel during the 3rd quarter valued at approximately $92,000.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Truist Financial reaffirmed a "buy" rating and set a $61.00 price target (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. BTIG Research lifted their price target on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a report on Saturday. Stephens reaffirmed an "overweight" rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $62.29.

Remove Ads

Insider Buying and Selling

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Siegal sold 1,092 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. This trade represents a 47.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,500 shares of company stock worth $466,200 in the last ninety days. Company insiders own 5.20% of the company's stock.

Vericel Trading Up 1.6 %

NASDAQ:VCEL traded up $0.80 during mid-day trading on Friday, hitting $49.56. 459,530 shares of the company's stock were exchanged, compared to its average volume of 419,587. The company has a 50 day simple moving average of $56.48 and a 200-day simple moving average of $51.92. Vericel Co. has a fifty-two week low of $39.12 and a fifty-two week high of $63.00. The firm has a market capitalization of $2.48 billion, a P/E ratio of 826.14 and a beta of 1.78.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.